The pharmaceutical industry in Pakistan continues to thrive, supported by rising domestic demand, healthcare innovation, and record-breaking export growth. In FY25 alone, pharma exports surged 34%, reaching $457 million—making it one of the fastest-growing export categories.
Here’s a quick snapshot of the Top 10 pharma companies listed on the Pakistan Stock Exchange (PSX) ranked by market capitalization (as of July 24, 2025):
🔹 GlaxoSmithKline Pakistan Limited (GLAXO) – $438M
🔹 Abbott Laboratories Pakistan Limited (ABOT) – $371M
🔹 Haleon Pakistan Limited (HALEON) – $330M
🔹 Highnoon Laboratories Limited (HINOON) – $202M
🔹 AGP Limited (AGP) – $189M
🔹 The Searle Company Limited (SEARL) – $167M
🔹 Hoechst Pakistan Limited (HPL) – $105M
🔹 Citi Pharma Limited (CPHL) – $66M
🔹 Macter International Limited (MACTER) – $62M
🔹 Ferozsons Laboratories Limited (FEROZ) – $60M
Why It Matters for Investors
-
Steady Growth: Pharma sector remains resilient even during economic slowdowns.
-
Export Momentum: Local companies tapping into international markets.
-
Domestic Demand: Rising population & healthcare needs keep demand high.
With multinationals scaling up investments and local companies expanding capacities, the sector offers strong long-term growth potential for investors.